Meeting
2013 ASCO Annual Meeting
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.
Authors
Richard A. Larson
The University of Chicago, Chicago, IL
Richard A. Larson , Andreas Hochhaus , Giuseppe Saglio , Dong-Wook Kim , Saengsuree Jootar , Philipp D. Le Coutre , Josy Reiffers , Ricardo Pasquini , Stuart L. Goldberg , Richard E. Clark , Charisse N. Kemp , Xiaolin Fan , Hans D. Menssen , Timothy P. Hughes , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00471497
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7052^)
DOI
10.1200/jco.2013.31.15_suppl.7052
Abstract #
7052^
Poster Bd #
36D
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
First Author: James E. Signorovitch
Poster
2013 ASCO Annual Meeting
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.
First Author: Giuseppe Saglio
Poster
2012 ASCO Annual Meeting
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).
First Author: Hagop Kantarjian
Poster
2013 ASCO Annual Meeting
Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up.
First Author: Nelson Spector